Failure to Achieve Growth in the mRNA-Targeting Small-Molecule Drug Market
First written in FY2023. 1 of 2 entries say "Worsened", first in FY2025. Latest entry: FY2025.
Veritas In Silico moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「The field of mRNA-targeted small-molecule drug discovery to which we belong is still at the research stage globally, and we believe that there is a low likelihood of a large market being established by 2030.」
The company explicitly states that a large market is unlikely to be established by 2030, while also indicating that the market could eventually reach a scale comparable to the existing market for protein-targeted small-molecule drugs. - FY2023First statedAnnual report
「However, if toxicity risks associated with mRNA as a drug-discovery target become apparent, or if the position of mRNA-targeted small-molecule drugs in the pharmaceutical market changes due to the development of promising next-generation drug-discovery approaches other than mRNA-targeted small-molecule drugs, the market may fail to expand as expected. If partners for joint drug-discovery research cannot be found as expected, our business, financial condition and operating results may also be affected.」
The company identifies toxicity risks, competition from other next-generation drug-discovery approaches, changes in market positioning and a shortage of partners as uncertainties affecting market growth.